Peptides DB
Research-centric peptide and protocol reference hub
Study 21 of 25Pasireotide literatureJCEM case reports · Case reportHigh-impact journal2026

Fourteen-year bridge to cure in occult ectopic ACTH syndrome: resection of a 3-mm pulmonary carcinoid.

Long-term use of somatostatin analogs may help stabilize patients with occult ectopic ACTH syndrome until surgical intervention can occur.

Read at JCEM case reportsAdd to compare

Where it sits

this study against the rest of the pasireotide corpus
1
Preclinical
16
Observational · this one
0
Open-label
3
Randomised
5
Reviews

Summary and findings

This case report describes a 68-year-old woman with severe ACTH-dependent hypercortisolism due to occult ectopic ACTH syndrome. She received long-acting release octreotide for over a decade, achieving sustained biochemical stability. In 2023, a 3-mm pulmonary carcinoid was discovered incidentally during breast cancer surgery, leading to the resolution of her EAS and recovery of adrenal function.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Not reported in abstract.2026

Abstract

The authors’ words, as JCEM case reports supplied them

Ectopic adrenocorticotropic hormone (ACTH) syndrome (EAS) often involves occult microtumors, making localization challenging. We report a 68-year-old woman with severe ACTH-dependent hypercortisolism in whom the primary tumor remained occult despite extensive imaging, including <sup>68</sup>Ga-tetraazacyclododecanetetraacetic acid-D-Phe(1)-Tyr(3)-octreotide positron emission tomography/computed tomography. Based on a positive octreotide challenge test, she received long-acting release octreotide for over a decade, achieving sustained biochemical stability. In 2020, she developed breast cancer, with the tumor being ACTH-negative on immunohistochemistry. In 2023, during resection of pulmonary metastases of the breast cancer, a 3-mm nodule was incidentally discovered in the adjacent lung tissue. Through close interdisciplinary coordination, the nodule was removed and was confirmed as an ACTH- and somatostatin receptor (SSTR) 2-positive pulmonary carcinoid. Thereafter, the EAS resolved completely with prompt recovery of adrenal function. In this case, intensive medical stabilization in occult EAS probably served as a strategic "bridge to surgery." Importantly, long-term biochemical control using somatostatin analogs facilitated prompt recovery of the hypothalamic-pituitary-adrenal axis immediately after tumor resection. This may also have preserved SSTR2 expression, potentially by mitigating cortisol-induced receptor downregulation, facilitating its eventual localization. This report shows that meticulous multidisciplinary communication during unrelated surgical procedures is indispensable for identifying radiologically occult lesions.

Elsewhere in the Pasireotide corpus

BApproach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026 · 80% of patients achieved hormonal control with biomarker-guided treatment.reviewBTirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.Endocrine journal · 2026 · n=1 · HbA1c decreased from 7.7% to 6.3% after switching to tirzepatide.HumanBTirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review.Endocrine journal · 2026 · n=1 · HbA1c decreased from 7.7% to 6.3%.HumanBCase Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation.Frontiers in endocrinology · 2023 · n=1 · Not reported in abstract.HumanAReduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial.Pituitary · 2026 · 6.2% (1.6%) of days with symptom exacerbations after switching to paltusotine, n=22, p<0.0001.HumanAPhase 1 Study of Paltusotine, a Novel Oral Once‑Daily, Nonpeptide Selective Somatostatin Receptor 2 Agonist, in Healthy Japanese Adults.Clinical pharmacology in drug development · 2026 · Elimination half-life (t<sub>1/2</sub>) was 24-28 h.Human